Spears Abacus Advisors LLC lowered its holdings in Celgene Corporation (NASDAQ:CELG) by 4.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 196,449 shares of the biopharmaceutical company’s stock after selling 9,981 shares during the period. Celgene accounts for 3.2% of Spears Abacus Advisors LLC’s investment portfolio, making the stock its 14th biggest position. Spears Abacus Advisors LLC’s holdings in Celgene were worth $25,513,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in CELG. Thompson Davis & CO. Inc. lifted its stake in shares of Celgene by 5.9% in the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 43 shares in the last quarter. Motco lifted its stake in shares of Celgene by 19.3% in the second quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 159 shares in the last quarter. Penserra Capital Management LLC acquired a new position in shares of Celgene in the second quarter worth about $129,000. Acropolis Investment Management LLC bought a new position in Celgene in the 2nd quarter worth approximately $144,000. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. grew its holdings in Celgene by 47.5% in the 1st quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 380 shares in the last quarter. 80.17% of the stock is owned by institutional investors and hedge funds.

Shares of Celgene Corporation (NASDAQ CELG) opened at $100.83 on Friday. The company has a market cap of $81,873.09, a price-to-earnings ratio of 16.25, a P/E/G ratio of 0.80 and a beta of 1.79. Celgene Corporation has a 52-week low of $94.55 and a 52-week high of $147.17. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52.

Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the consensus estimate of $1.87 by $0.04. The business had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm’s revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.58 EPS. equities analysts predict that Celgene Corporation will post 6.67 earnings per share for the current fiscal year.

Several analysts recently issued reports on the company. Vetr upgraded Celgene from a “buy” rating to a “strong-buy” rating and set a $148.32 price objective for the company in a report on Thursday, August 10th. UBS cut shares of Celgene from a “strong-buy” rating to a “market perform” rating and set a $160.00 target price for the company. in a research note on Thursday, October 26th. BMO Capital Markets cut their target price on shares of Celgene from $163.00 to $148.00 and set an “outperform” rating for the company in a research note on Friday, October 27th. Jefferies Group reiterated a “buy” rating and issued a $160.00 target price on shares of Celgene in a research note on Friday, September 15th. Finally, BTIG Research reiterated a “neutral” rating on shares of Celgene in a research note on Tuesday, September 5th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have issued a buy rating and two have assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $139.57.

In other Celgene news, Director Gilla Kaplan sold 9,250 shares of the business’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the sale, the director now directly owns 85,551 shares of the company’s stock, valued at approximately $12,110,599.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Terrie Curran sold 1,727 shares of the business’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the sale, the insider now directly owns 3,925 shares in the company, valued at $564,768.25. The disclosure for this sale can be found here. Insiders sold a total of 20,227 shares of company stock worth $2,843,956 over the last ninety days. 0.95% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: “Spears Abacus Advisors LLC Has $25.51 Million Holdings in Celgene Corporation (CELG)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/12/01/spears-abacus-advisors-llc-has-25-51-million-holdings-in-celgene-corporation-celg.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.